Research + Development
Saronic Biotechnology, Inc. is preparing to launch a Phase I/II trial of its lead therapeutic, SBI1997.
Program Overview
Clinical Programs: SBI1997
Saronic Biotechnology, Inc. is preparing to launch a Phase I/II trial of its lead therapeutic, SBI1997, to treat patients with hepatocellular carcinoma (HCC) in early 2016. SBI1997 will be offered to patients in two clinical indications:
- AUDIT Trial (Adjuvant HCC): This randomized Phase I/II trial will offer SBI1997 to HCC patients in the post-surgical setting with the aim of preventing cancer recurrence.
Therapeutic Discovery Pipeline
- Target Cell Modulation Program: Identification of proprietary compounds to selectively reduce inhibitory immune cells, resulting in an impactful anti-cancer response.
- Novel Molecular Target Program: Development of additional therapeutics for HCC based on molecular targets identified through dedicated genetic sequencing.